AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27398874 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent QI strategy
Number of subjects: 1146
Study 27398874 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1146
Study 24752908 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 416
Number of subjects: 0
Study 24131877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative social risk score (based on maternal reports of intimate partner violence, food insecurity, housing insecurity, maternal depressive symptoms, maternal substance use, father's incarceration)
Number of subjects: 1589
Study 24131877 — intervention group
Group type: EXPERIMENTAL
Intervention: Externalizing behavioral problems (measured with the Child Behavior Checklist)
Number of subjects: 1589
Study 24131877 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration
Number of subjects: 1589
Study 24131877 — intervention group
Group type: EXPERIMENTAL
Intervention: Watching more than 2 hours of television per day
Number of subjects: 1589
Study 20299990 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop anaesthesia delivery system (CLADS) with continuous infusion of propofol
Number of subjects: 41
Study 20299990 — intervention group
Group type: COMPARATOR
Intervention: Manual administration of propofol adjusted by clinician
Number of subjects: 41
Study 18619256 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhi‐Xin‐Fang combined with standard western medicines
Number of subjects: 62
Study 18619256 — intervention group
Group type: COMPARATOR
Intervention: Standard western medical therapy
Number of subjects: 62
Study 15150183 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g once a day
Number of subjects: 1558
Study 15150183 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam 3.375 g every 6 h
Number of subjects: 1558
Study 11440287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Number of subjects: 90
Study 11440287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 20 mg
Number of subjects: 90
Study 11440287 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (both doses)
Number of subjects: 90
Study 9772043 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 24
Study 9772043 — intervention group
Group type: COMPARATOR
Intervention: 6-methylprednisolone (prednisolone)
Number of subjects: 24
Study 7828692 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (40 mg)
Number of subjects: 8
Study 7828692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7828692 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lysine acetylsalicylate (modified protocol)
Number of subjects: 8
Study 3136331 — intervention group
Group type: EXPERIMENTAL
Intervention: sorbinil (250 mg per day)
Number of subjects: 16
Study 31352458 — intervention group
Group type: EXPERIMENTAL
Intervention: Air tamponade
Number of subjects: 72
Study 31352458 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 72
Study 31352458 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phacoemulsification
Number of subjects: 72
Study 31703468 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP (hypertrophic loading): five times 10 repetitions at 70% of 1RM with 2 minutes inter-set rest
Number of subjects: 10
Study 31703468 — intervention group
Group type: EXPERIMENTAL
Intervention: MAX (maximum strength loading): 15 times one repetition at 100% of 1RM with 3 minutes inter-set rest
Number of subjects: 10
Study 28329181 — intervention group
Group type: EXPERIMENTAL
Intervention: Gatifloxacin
Number of subjects: 2092
Study 28329181 — intervention group
Group type: COMPARATOR
Intervention: Cefixime
Number of subjects: 2092
Study 28329181 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 2092
Study 28329181 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin
Number of subjects: 2092
Study 28329181 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 2092
Study 25465941 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull
Number of subjects: 20
Study 25465941 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 20
Study 25465941 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Bull + Mental Stress
Number of subjects: 20
Study 25465941 — intervention group
Group type: COMPARATOR
Intervention: Water + Mental Stress
Number of subjects: 20
Study 23054350 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 179
Study 23054350 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 179
Study 23054350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecologically‐Based Family Therapy (EBFT)
Number of subjects: 179
Study 21952349 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote postischemic conditioning (three 5-min cycles of ischemia by inflation of a cuff on the non-dominant arm to 200 mm Hg)
Number of subjects: 320
Study 21952349 — intervention group
Group type: COMPARATOR
Intervention: Placebo (uninflated cuff)
Number of subjects: 320
Study 21952349 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote postischemic conditioning
Number of subjects: 320
Study 21952349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 18829444 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg/d)
Number of subjects: 10739
Study 18829444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10739
Study 16495069 — intervention group
Group type: EXPERIMENTAL
Intervention: Single drain (group A)
Number of subjects: 119
Study 16495069 — intervention group
Group type: COMPARATOR
Intervention: Two drains (group B)
Number of subjects: 119
Study 12908663 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 12908663 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study 12908663 — intervention group
Group type: COMPARATOR
Intervention: Atypical antipsychotics (2000 estimates)
Number of subjects: 0
Study 11205461 — intervention group
Group type: EXPERIMENTAL
Intervention: Five years of adjuvant tamoxifen
Number of subjects: 577
Study 11205461 — intervention group
Group type: COMPARATOR
Intervention: Two years of adjuvant tamoxifen
Number of subjects: 577
Study 11205461 — intervention group
Group type: EXPERIMENTAL
Intervention: Five years of tamoxifen for erbB2-negative patients
Number of subjects: 577
Study 11205461 — intervention group
Group type: EXPERIMENTAL
Intervention: Five years of tamoxifen for erbB2-positive patients
Number of subjects: 577
Study 11205461 — intervention group
Group type: EXPERIMENTAL
Intervention: Five years of tamoxifen for ER-positive patients
Number of subjects: 577
Study 9093633 — intervention group
Group type: EXPERIMENTAL
Intervention: D-P (dapsone-pyrimethamine)
Number of subjects: 249
Study 9093633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 8245996 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvastus arthrotomy
Number of subjects: 20
Study 8245996 — intervention group
Group type: COMPARATOR
Intervention: Paramedian arthrotomy
Number of subjects: 20
Study 2880755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 1.5 g every 8th hour for 24 hours followed by cefadroxil 0.5 g twice daily for 6 days
Number of subjects: 2
Study 2880755 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 2
Study 2880755 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime and cefadroxil (treatment)
Number of subjects: 2
Study 30801523 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous Human Adult Liver‐derived Progenitor Cells (HepaStem)
Number of subjects: 20
Study 30248126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 714
Study 30248126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diversity
Number of subjects: 714
Study 27428596 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing on a 65cm elevated platform
Number of subjects: 0
Study 27428596 — intervention group
Group type: COMPARATOR
Intervention: Floor level standing
Number of subjects: 0
Study 24405007 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment intervention using a handheld, vibrating stimulation device
Number of subjects: 11
Study 24405007 — intervention group
Group type: COMPARATOR
Intervention: Wait list control
Number of subjects: 11
Study 22968527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g over 10 minutes followed by 1 g over eight hours)
Number of subjects: 13273
Study 22968527 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 13273
Study 19882541 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 81
Study 19882541 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (GDx)
Number of subjects: 81
Study 19882541 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual evoked potentials (VEP)
Number of subjects: 81
Study 17563186 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood (induced by viewing happy movie clips)
Number of subjects: 0
Study 17563186 — intervention group
Group type: COMPARATOR
Intervention: Sad mood (induced by viewing sad movie clips)
Number of subjects: 0
Study 17563186 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood (induced by viewing neutral movie clips)
Number of subjects: 0
Study 15264116 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg/day for 12 weeks
Number of subjects: 46
Study 15264116 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 46
Study 12271297 — intervention group
Group type: EXPERIMENTAL
Intervention: AE-941 at 240 mL/d
Number of subjects: 49
Study 12271297 — intervention group
Group type: EXPERIMENTAL
Intervention: AE-941 at 120 mL/d
Number of subjects: 49
Study 12271297 — intervention group
Group type: EXPERIMENTAL
Intervention: AE-941 at 60 mL/d
Number of subjects: 49
Study 12271297 — intervention group
Group type: EXPERIMENTAL
Intervention: AE-941 at 30 mL/d
Number of subjects: 49
Study 12271297 — intervention group
Group type: EXPERIMENTAL
Intervention: AE-941 (all doses)
Number of subjects: 49
Study 12271297 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonserious drug-related adverse events
Number of subjects: 49
Study 9824882 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients on visual continuous performance test (CPT)
Number of subjects: 48
Study 9824882 — intervention group
Group type: COMPARATOR
Intervention: Normal controls on visual continuous performance test (CPT)
Number of subjects: 48
Study 9824882 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults with developmental attentional/learning disorders on visual continuous performance test (CPT)
Number of subjects: 48
Study 7911530 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (0.15 mg/kg, intravenous)
Number of subjects: 30
Study 7911530 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (intravenous)
Number of subjects: 30
Study 2594919 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.125 mg
Number of subjects: 45
Study 2594919 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg
Number of subjects: 45
Study 2594919 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 45
Study 2594919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 30965344 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 25 mg/m2 daily for 4 days, repeated every 28 days over 32 weeks (first trial)
Number of subjects: 22
Study 30965344 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 50 mg/m2 every 4 weeks for 12 weeks, followed by 25 mg/m2 every 4 weeks for 36 weeks (second trial)
Number of subjects: 22
Study 30965344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined analysis of both trials
Number of subjects: 22
Study 28235859 — intervention group
Group type: EXPERIMENTAL
Intervention: 12° head-down tilt (HDT) with ambient air for 29 hours
Number of subjects: 0
Study 28235859 — intervention group
Group type: EXPERIMENTAL
Intervention: 12° head-down tilt (HDT) with 0.5% CO2 for 29 hours
Number of subjects: 0
Study 26358516 — intervention group
Group type: EXPERIMENTAL
Intervention: Intubating-laryngeal mask airway (I-LMA)
Number of subjects: 29
Study 26358516 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 29
Study 23364890 — intervention group
Group type: EXPERIMENTAL
Intervention: K3 prosthetic foot
Number of subjects: 10
Study 23364890 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training
Number of subjects: 10
Study 23364890 — intervention group
Group type: COMPARATOR
Intervention: K1/K2 prosthetic feet
Number of subjects: 10
Study 21638048 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene (TOR) 40 mg daily
Number of subjects: 0
Study 21638048 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole (ANA) 1 mg daily
Number of subjects: 0
Study 18684571 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM) intervention
Number of subjects: 123
Study 18684571 — intervention group
Group type: COMPARATOR
Intervention: Standard methadone treatment
Number of subjects: 123
Study 16722959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention for weaning patients from mechanical ventilation
Number of subjects: 0
Study 14518142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei and Lactobacillus acidophilus (10(10)-10(12) CFU/g)
Number of subjects: 89
Study 14518142 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (10(10)-10(12) CFU/g)
Number of subjects: 89
Study 14518142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pasteurized cow milk)
Number of subjects: 89
Study 16881093 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic synovectomy (AS) followed by intraarticular corticosteroid (IAC) treatment
Number of subjects: 22
Study 16881093 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic synovectomy (AS)
Number of subjects: 22
Study 10677890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized anaesthetics (10 ml of 1% trimecain)
Number of subjects: 80
Study 10677890 — intervention group
Group type: COMPARATOR
Intervention: Isotonic chlorine solution
Number of subjects: 80
Study 8735490 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked radiotherapy
Number of subjects: 90
Study 8735490 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 90
Study 1837260 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg etodolac twice daily for 12 weeks
Number of subjects: 60
Study 1837260 — intervention group
Group type: COMPARATOR
Intervention: 20 mg piroxicam once daily for 12 weeks
Number of subjects: 60
Study 7060822 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% miconazole nitrate aerosol spray powder
Number of subjects: 46
Study 7060822 — intervention group
Group type: COMPARATOR
Intervention: 1% tolnaftate aerosol spray powder
Number of subjects: 46
Study 28927706 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab (140 mg every 2 weeks or 420 mg once per month)
Number of subjects: 27564
Study 25562510 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional incidental training (FIT) program consisting of 4 extra episodes of functional exercise daily during SSR
Number of subjects: 60
Study 25562510 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional incidental training (FIT) program
Number of subjects: 60
Study 24673819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous silibinin (20 mg/kg daily for 14 days)
Number of subjects: 20
Study 24673819 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 20
Study 22472267 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise (LIE) - exercise at 10% below ventilatory threshold (VT)
Number of subjects: 8
Study 22472267 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise (HIE) - exercise at 10% above VT
Number of subjects: 8
Study 22472267 — intervention group
Group type: COMPARATOR
Intervention: Control - seated for 30 min
Number of subjects: 8
Study 19233016 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Number of subjects: 78
Study 17071000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for chronic pain, specific details on dosage and duration not available.
Number of subjects: 0
Study 15351240 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvessel density evaluation using immunohistochemical localization of vWF, cytokeratin 34BE-12, and HSPG.
Number of subjects: 50
Study 15351240 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvessel density evaluation within 2 standard deviations (SD) of the mean.
Number of subjects: 50
Study 15351240 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokeratin and HSPG localization patterns.
Number of subjects: 50
Study 15351240 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of HGPIN for microvessel density by localization of vWF.
Number of subjects: 50
Study 11588683 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (123 ml of 300 mgl/ml)
Number of subjects: 75
Study 11588683 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (112 ml of 335 mgl/ml)
Number of subjects: 75
Study 11588683 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (100 ml of 370 mgl/ml)
Number of subjects: 75
Study 11588683 — intervention group
Group type: COMPARATOR
Intervention: Control (lower iodine concentrations)
Number of subjects: 75
Study 9540151 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg propacetamol
Number of subjects: 80
Study 9540151 — intervention group
Group type: COMPARATOR
Intervention: 0.2 mg/kg morphine
Number of subjects: 80
Study 8022626 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low-dose morphine (2 mg) and bupivacaine (25 mg)
Number of subjects: 13
Study 8022626 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine (25 mg)
Number of subjects: 13
Study 8022626 — intervention group
Group type: COMPARATOR
Intervention: Morphine (2 mg)
Number of subjects: 13
Study 8022626 — intervention group
Group type: COMPARATOR
Intervention: All treatments (Combination, Bupivacaine, Morphine)
Number of subjects: 13
Study 2645916 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (1 mg/kg po)
Number of subjects: 8
Study 2645916 — intervention group
Group type: COMPARATOR
Intervention: Water alone (Control)
Number of subjects: 8
Study 30882242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro II (a capsule containing 3 strains, 109 cfu per strain)
Number of subjects: 40
Study 30882242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro I (a capsule containing 3 strains, 109 cfu per strain)
Number of subjects: 40
Study 30882242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29096627 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 88 μg
Number of subjects: 355
Study 29096627 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 355
Study 29096627 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin 350 μg
Number of subjects: 355
Study 29096627 — intervention group
Group type: EXPERIMENTAL
Intervention: Revefenacin ≥88 μg
Number of subjects: 355
Study 29096627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study 26414564 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated day shifts (circadian alignment)
Number of subjects: 13
Study 26414564 — intervention group
Group type: COMPARATOR
Intervention: Simulated night shifts (circadian misalignment)
Number of subjects: 13
Study 24076063 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 24
Study 24076063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 21242072 — intervention group
Group type: EXPERIMENTAL
Intervention: C. laevigata (400 mg three times a day)
Number of subjects: 49
Study 21242072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 20205984 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg isoflavones
Number of subjects: 45
Study 20205984 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg isoflavones
Number of subjects: 45
Study 20205984 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg isoflavones
Number of subjects: 45
Study 20205984 — intervention group
Group type: COMPARATOR
Intervention: No supplement (control)
Number of subjects: 45
Study 17919059 — intervention group
Group type: EXPERIMENTAL
Intervention: Air abrasion
Number of subjects: 60
Study 17919059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical brushing
Number of subjects: 60
Study 17919059 — intervention group
Group type: EXPERIMENTAL
Intervention: Bur treatment (Intensive bur FG 40D4)
Number of subjects: 60
Study 17919059 — intervention group
Group type: COMPARATOR
Intervention: Admira seal (Voco)
Number of subjects: 60
Study 17919059 — intervention group
Group type: COMPARATOR
Intervention: Delton FS+ (Dentsply)
Number of subjects: 60
Study 16298723 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivationally enhanced phone counseling (MEC)
Number of subjects: 275
Study 16298723 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 275
Study 11862352 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 60
Study 11862352 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (10 mg)
Number of subjects: 60
Study 11862352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10202368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% eye drops
Number of subjects: 34
Study 10202368 — intervention group
Group type: COMPARATOR
Intervention: Sodium cromoglycate 2% eye drops
Number of subjects: 34
Study 7762909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir, 2.5 mg/kg body weight administered intravenously on every day that antilymphocyte antibody therapy was administered
Number of subjects: 113
Study 7762909 — intervention group
Group type: COMPARATOR
Intervention: No anticytomegalovirus therapy
Number of subjects: 113
Study 2306420 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg HCl for 4 days
Number of subjects: 10
Study 7423172 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 145